Markets:

Overview

News

Currencies

International

Treasuries

Merck & Co (NY:MRK)

116.19 +0.75 (+0.65%)

Streaming Delayed Price Updated: 10:12 AM EDT, Mar 17, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Merck & Co

< Previous 1 2

...

18 19 20 21 22 23 24 25 26

...

99 100 Next >

Peering Into Merck & Co's Recent Short Interest ↗

June 30, 2025

Via Benzinga

1 Profitable Stock to Consider Right Now and 2 to Think Twice About

June 30, 2025

Not all profitable companies are built to last - some rely on outdated models or unsustainable advantages. Just because a business is in the green today doesn’t mean it will thrive tomorrow.

Via StockStory

3 Absurdly Cheap Stocks Ready for a Breakout ↗

June 28, 2025

All three stocks are poised to go higher.

Via The Motley Fool

RFK Jr's CDC Panel Recommends Merck's RSV Shot For Infants ↗

June 27, 2025

CDC panel backs Merck's Enflonsia for RSV prevention in infants; FDA-approved therapy reduced hospitalizations by 84% in clinical trials.

Via Benzinga

CDC Vaccine Panel Overhauled by RFK Jr. Votes To Drop Mercury Preservative, Critics Sound Alarm ↗

June 26, 2025

The panel also voted to recommend Merck’s RSV antibody drug Enflonsia for newborns whose mothers didn’t receive prenatal protection.

Via Stocktwits

5 Biotech Stocks with Highly Anticipated Pending Results ↗

June 26, 2025

Via Stocktwits

Topics Intellectual Property

Elanco Animal Health Gets Its Bite Back, Pipeline Efforts Earn Praise ↗

June 26, 2025

Elanco upgraded to Outperform by William Blair as pipeline gains traction and EMA backs Zenrelia ahead of expected Q3 approval.

Via Benzinga

ACIP Recommends Use of Merck’s ENFLONSIA™ (clesrovimab-cfor) for Prevention of Respiratory Syncytial Virus (RSV) Lower Respiratory Tract Disease in Infants Younger than 8 Months of Age Born During or Entering Their First RSV Season

June 26, 2025

From Merck & Co., Inc.

Via Business Wire

2 Stocks Too Cheap to Ignore at These Prices ↗

June 26, 2025

Via The Motley Fool

Topics Artificial Intelligence Lawsuit

RFK Jr. Overhauls CDC Vaccine Panel, Sparking Expert Backlash, Boycott From Top Medical Group ↗

June 26, 2025

Health Secretary Robert F. Kennedy Jr.'s newly reconstituted vaccine advisory panel is facing criticism from medical experts.

Via Benzinga

Merck to Hold Investor Event to Highlight Advancing Research Pipeline for HIV Treatment and Prevention

June 24, 2025

From Merck & Co., Inc.

Via Business Wire

Merck's Hypertension Drug Cuts Clinical Worsening Risk In Over 70% Of Patients On Double Background Therapy ↗

June 23, 2025

Merck's Winrevair reduced clinical worsening in PAH patients in the Phase 3 HYPERION trial, building on prior positive study outcomes.

Via Benzinga

Merck Announces Phase 3 HYPERION Study of WINREVAIR™ (sotatercept-csrk) Met Primary Endpoint in Recently Diagnosed Adults with Pulmonary Arterial Hypertension (PAH)

June 23, 2025

From Merck & Co., Inc.

Via Business Wire

Obesity Drugs Help With Weight Loss But Are Adding Fat Elsewhere ↗

June 20, 2025

The U.S. trade deficit with Ireland has surged as $36 billion in hormone shipments for weight-loss and diabetes drugs were flown in to meet demand and avoid tariffs.

Via Benzinga

Mark Cuban Corrects Elizabeth Warren As She Slams JNJ, PFE For Higher Prices And Zero Taxes On Big Pharma: 'PBMs Corrupt Healthcare' ↗

June 20, 2025

A debate over the healthcare system erupted on X, pitting Mark Cuban against Elizabeth Warren over the root causes of soaring drug prices.

Via Benzinga

2 Reasons to Watch MRK and 1 to Stay Cautious

June 19, 2025

Shareholders of Merck would probably like to forget the past six months even happened. The stock dropped 20.3% and now trades at $79.30. This might have investors contemplating their next move.

Via StockStory

Topics Supply Chain

Nobody Wants To Touch Healthcare Stocks Now – That Might Be A Big Mistake ↗

June 18, 2025

Healthcare stocks are lagging the market by the widest margin since 2008. Analysts and valuation trends point to a rebound.

Via Benzinga

Wall Street's Most Accurate Analysts Give Their Take On 3 Health Care Stocks Delivering High-Dividend Yields ↗

June 18, 2025

Via Benzinga

MERCK & CO. INC. (NYSE:MRK) - A Strong Dividend Stock with Solid Fundamentals ↗

June 18, 2025

MERCK & CO. (NYSE:MRK) is a top dividend stock with a 3.96% yield, strong profitability, and solid financial health, making it a compelling choice for income investors.

Via Chartmill

IDeate-Prostate01 Phase 3 Trial of Ifinatamab Deruxtecan Initiated in Patients with Pretreated Metastatic Castration-Resistant Prostate Cancer

June 18, 2025

From Merck & Co., Inc.

Via Business Wire

2 Dividend Stocks to Buy and Never Sell ↗

June 18, 2025

Via The Motley Fool

Topics Lawsuit

3 Mega-Cap Stocks with Competitive Advantages

June 18, 2025

"Too big to fail" is how we would describe the megacap stocks in this article today. While they will likely stand the test of time, it’s not all sunshine and rainbows as their scale can limit their...

Via StockStory

Elizabeth Warren, Jan Schakowsky Reportedly Seek Answers From Pfizer, Amgen, And Others On Low Federal Tax Bills ↗

June 17, 2025

The Democratic lawmakers alleged that pharmaceutical companies avoided paying U.S. tax bills by shifting their profits to offshore subsidiaries in jurisdictions with significantly lower tax rates, such...

Via Stocktwits

Topics Government

These Were the 2 Worst-Performing Stocks in the Dow Jones Industrial Average in May 2025 ↗

June 14, 2025

The Dow Jones index could have fared better in May if not for these two stocks.

Via The Motley Fool

Topics Government Intellectual Property Lawsuit

Merck's Keytruda Secures FDA Nod For Head And Neck Cancer As First Immunotherapy For Use Around Surgery ↗

June 13, 2025

Merck's Keytruda receives FDA approval for head and neck cancer after showing improved event-free survival in Phase 3 KEYNOTE-689 trial.

Via Benzinga

Merck Gets FDA Approval For Keytruda To Treat A Broader Population Of Head And Neck Cancer Patients: Retail Stays Bullish ↗

June 13, 2025

In the U.S., it is estimated there will be approximately 72,680 new cases of head and neck cancer diagnosed and more than 16,680 deaths from the disease in 2025, Merck said.

Via Stocktwits

Topics Death

FDA Approves KEYTRUDA® (pembrolizumab) for PD-L1+ Resectable Locally Advanced Head & Neck Squamous Cell Carcinoma as Neoadjuvant Treatment, Continued as Adjuvant Treatment Combined With Radiotherapy With or Without Cisplatin Then as a Single Agent

June 13, 2025

From Merck & Co., Inc.

Via Business Wire

Merck Animal Health Receives EU CVMP Positive Opinion for NUMELVI™ (atinvicitinib) Tablets for Dogs

June 12, 2025

From Merck & Co., Inc.

Via Business Wire

RFK Jr. Appointee To CDC Advisory Committee Was A Paid Expert In Merck's Gardasil Lawsuit ↗

June 12, 2025

Martin Kulldorff, appointed by RFK Jr. to a federal vaccine panel, previously earned $33K as an expert witness in lawsuits targeting Merck's Gardasil vaccine.

Via Benzinga

Topics Lawsuit

10 Health Care Stocks With Whale Alerts In Today's Session ↗

June 12, 2025

Via Benzinga

< Previous 1 2

...

18 19 20 21 22 23 24 25 26

...

99 100 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.